Literature DB >> 15561802

Steroid sulfatase: molecular biology, regulation, and inhibition.

M J Reed1, A Purohit, L W L Woo, S P Newman, B V L Potter.   

Abstract

Steroid sulfatase (STS) is responsible for the hydrolysis of aryl and alkyl steroid sulfates and therefore has a pivotal role in regulating the formation of biologically active steroids. The enzyme is widely distributed throughout the body, and its action is implicated in physiological processes and pathological conditions. The crystal structure of the enzyme has been resolved, but relatively little is known about what regulates its expression or activity. Research into the control and inhibition of this enzyme has been stimulated by its important role in supporting the growth of hormone-dependent tumors of the breast and prostate. STS is responsible for the hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate to estrone and dehydroepiandrosterone, respectively, both of which can be converted to steroids with estrogenic properties (i.e., estradiol and androstenediol) that can stimulate tumor growth. STS expression is increased in breast tumors and has prognostic significance. The role of STS in supporting tumor growth prompted the development of potent STS inhibitors. Several steroidal and nonsteroidal STS inhibitors are now available, with the irreversible type of inhibitor having a phenol sulfamate ester as its active pharmacophore. One such inhibitor, 667 COUMATE, has now entered a phase I trial in postmenopausal women with breast cancer. The skin is also an important site of STS activity, and deficiency of this enzyme is associated with X-linked ichthyosis. STS may also be involved in regulating part of the immune response and some aspects of cognitive function. The development of potent STS inhibitors will allow investigation of the role of this enzyme in physiological and pathological processes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15561802     DOI: 10.1210/er.2004-0003

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  111 in total

1.  Sex hormones and the risk of incident prostate cancer.

Authors:  Nicholas A Daniels; Carrie M Nielson; Andrew R Hoffman; Douglas C Bauer
Journal:  Urology       Date:  2010-05-07       Impact factor: 2.649

2.  Adrenal androgens rescue prostatic dihydrotestosterone production and growth of prostate cancer cells after castration.

Authors:  Yue Wu; Li Tang; Gissou Azabdaftari; Elena Pop; Gary J Smith
Journal:  Mol Cell Endocrinol       Date:  2019-02-23       Impact factor: 4.102

3.  Fetal hypothalamus-pituitary-adrenal responses to estradiol sulfate.

Authors:  Charles E Wood
Journal:  Endocrinology       Date:  2011-09-27       Impact factor: 4.736

4.  Evidence that the Y chromosome influences autoimmune disease in male and female mice.

Authors:  Cory Teuscher; Rajkumar Noubade; Karen Spach; Benjamin McElvany; Janice Y Bunn; Parley D Fillmore; James F Zachary; Elizabeth P Blankenhorn
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-15       Impact factor: 11.205

5.  Glucosamine-6-sulfamate analogues of heparan sulfate as inhibitors of endosulfatases.

Authors:  Mathias Schelwies; Diana Brinson; Shuhei Otsuki; Young-Hoon Hong; Martin K Lotz; Chi-Huey Wong; Sarah R Hanson
Journal:  Chembiochem       Date:  2010-11-22       Impact factor: 3.164

Review 6.  Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review.

Authors:  Lina Schiffer; Lise Barnard; Elizabeth S Baranowski; Lorna C Gilligan; Angela E Taylor; Wiebke Arlt; Cedric H L Shackleton; Karl-Heinz Storbeck
Journal:  J Steroid Biochem Mol Biol       Date:  2019-07-27       Impact factor: 4.292

7.  Androgen deprivation by activating the liver X receptor.

Authors:  Jung Hoon Lee; Haibiao Gong; Shaheen Khadem; Yi Lu; Xiang Gao; Song Li; Jian Zhang; Wen Xie
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

8.  The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer.

Authors:  Paul A Foster; L W Lawrence Woo; Barry V L Potter; Michael J Reed; Atul Purohit
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

Review 9.  A review of coumarin derivatives in pharmacotherapy of breast cancer.

Authors:  Musiliyu A Musa; John S Cooperwood; M Omar F Khan
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 10.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery.

Authors:  Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.